
pmid: 21177324
handle: 11365/1152784 , 10807/31067
Circulating T cells and monocytes expressing T-bet, pSTAT1 and pSTAT3 increase in relapsing-remitting multiple sclerosis (RRMS) during relapse. Natalizumab (NZB) is an effective drug in RRMS, but exacerbation of the disease after its discontinuation has been described in some patients. The aim of this research was to study the effect of NZB treatment on circulating lymphomonocyte subpopulations expressing T-bet, pSTAT1, pSTAT3 and CD4+CD25+Foxp3+ regulatory T cells. Flow cytometry was used to evaluate the percentages of circulating CD4+ and CD8+ T cells, CD14+ monocytes and B cells expressing T-bet, pSTAT1, and pSTAT3, and CD4+CD25+Foxp3+ regulatory T cells from RRMS patients before and after 6-12 NZB infusions. In NZB-treated RRMS patients, the percentages of CD4+pSTAT1+ and CD8+pSTAT1+ T cells, CD14+pSTAT1+ monocytes, CD4+T-bet+, CD8+T-bet+ and CD4+pSTAT3+ T cells and CD14+pSTAT3+ monocytes increased after 12 drug infusions and were similar to those observed in untreated relapsing RRMS patients. Otherwise in vitro NZB exposure of peripheral blood mononuclear cells from untreated RRMS patients and controls had no effect. It was concluded that NZB treatment determines an accumulation of CD4+pSTAT1+, CD8+pSTAT1+, CD4+T-bet+, CD8+T-bet+ and CD4+STAT3+ T cells in peripheral blood that may account for the exacerbation of the disease observed in some patients after the discontinuation of the drug.
Adult, CD4-Positive T-Lymphocytes, Male, T cells, 610, CD8-Positive T-Lymphocytes, T-bet, multiple sclerosis, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Relapsing-Remitting, pSTAT3, 616, pSTAT1, Humans, Immunologic Factors, B cells, monocytes, multiple sclerosis, Natalizumab, pSTAT1, pSTAT3, T-bet, T cells, Cells, Cultured, B cells, Analysis of Variance, Chi-Square Distribution, Natalizumab, Interleukin-2 Receptor alpha Subunit, Antibodies, Monoclonal, Forkhead Transcription Factors, Middle Aged, Flow Cytometry, Italy, Case-Control Studies, Female, monocytes
Adult, CD4-Positive T-Lymphocytes, Male, T cells, 610, CD8-Positive T-Lymphocytes, T-bet, multiple sclerosis, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Relapsing-Remitting, pSTAT3, 616, pSTAT1, Humans, Immunologic Factors, B cells, monocytes, multiple sclerosis, Natalizumab, pSTAT1, pSTAT3, T-bet, T cells, Cells, Cultured, B cells, Analysis of Variance, Chi-Square Distribution, Natalizumab, Interleukin-2 Receptor alpha Subunit, Antibodies, Monoclonal, Forkhead Transcription Factors, Middle Aged, Flow Cytometry, Italy, Case-Control Studies, Female, monocytes
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 32 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
